Rheumatology

Smart Tendering Policies Unlock Greater Biosimilar Savings

March 20th 2025

By Skylar Jeremias

Article

Tendering emerged as the most effective strategy for reducing costs and increasing biosimilar uptake in the retail setting, while price-linked discounts and prescribing quotas have shown mixed or uncertain results.

More Ustekinumab Biosimilars Join US Market Share Fight

March 13th 2025

By Skylar Jeremias

Article

Celltrion and Formycon with Fresenius Kabi launched their respective ustekinumab biosimilars (Steqeyma and Otulfi), joining 4 others that launched earlier this year.

Updates on the Use of Biosimilars for Pediatric Patients With Rheumatic Disease

March 12th 2025

By Sabina Alikhanov Palmieri, PharmD

Article

Although more research is needed in pediatric patients, biosimilars could improve treatment access and reduce costs.

Pharmacists Play a Crucial Role in Adalimumab Biosimilars for Patient Care

March 5th 2025

By Kennedy Ferruggia

Article

Adalimumab biosimilars differ from adalimumab in approved indications, concentration and dosage, and formulation.

Adalimumab Biosimilar Switching Policy Shows Long-Term Success in IBD

February 26th 2025

By Skylar Jeremias

Article

Patients with inflammatory bowel disease (IBD) who switched from reference adalimumab (Humira) to a biosimilar under a mandatory nonmedical switching policy maintained long-term safety, efficacy, and treatment persistence comparable to those who remained on the originator drug, according to a Canadian study.

3 Ustekinumab Biosimilars Launch on US Market

February 25th 2025

By Skylar Jeremias

Article

Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara (ustekinumab), one of the most profitable drugs in the world.

Resolution of Injection Site Reactions After Switching to Adalimumab Biosimilar

February 22nd 2025

By Deana Ferreri, PhD

Article

A 15-year-old girl with ulcerative colitis who developed injection site reactions to the adalimumab reference product was successfully switched to the biosimilar LBAL without recurrence of symptoms, demonstrating the safety and effectiveness of switching for medical reasons, likely due to an allergic reaction to an excipient in the originator.

Disease Activity, Safety Remain Following Switch From Infliximab Biosimilar to Remicade in IBD

February 15th 2025

By Deana Ferreri, PhD

Article

Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or safety in inflammatory bowel disease (IBD), according to a prospective cohort study.

Psoriasis Biosimilars Saved VA $67 Million in 2023

February 12th 2025

By Skylar Jeremias

Article

The Department of Veterans Affairs (VA) saved $67 million in 2023 through its strong adoption of biosimilars to curb the high costs of biologic therapies to treat chronic disease.

Welcome Wezlana: Using Adalimumab to Predict Ustekinumab Market Potential

February 10th 2025

By Dracey Poore

Article

2025 marks a pivotal year for biosimilars with Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey Poore, MS, of Cardinal Health.